VanEck Biotech ETF (BBH)
| Assets | $531.74M |
| Expense Ratio | 0.35% |
| PE Ratio | 12.66 |
| Shares Out | 3.17M |
| Dividend (ttm) | $0.75 |
| Dividend Yield | 0.45% |
| Ex-Dividend Date | Dec 19, 2022 |
| Payout Ratio | 6.26% |
| 1-Year Return | +0.55% |
| Volume | 4,507 |
| Open | 167.10 |
| Previous Close | 166.02 |
| Day's Range | 166.22 - 167.75 |
| 52-Week Low | 131.12 |
| 52-Week High | 170.25 |
| Beta | 0.85 |
| Holdings | 26 |
| Inception Date | Dec 20, 2011 |
About BBH
The VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is managed by VanEck.
Top 10 Holdings
61.14% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 11.23% |
| Gilead Sciences, Inc. | GILD | 8.18% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.32% |
| Moderna, Inc. | MRNA | 5.66% |
| IQVIA Holdings Inc. | IQV | 5.39% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.14% |
| Biogen Inc. | BIIB | 4.84% |
| BeiGene, Ltd. | BGNE | 4.62% |
| Illumina, Inc. | ILMN | 4.48% |
| ICON PLC | ICLR | 4.27% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 19, 2022 | $0.7488 | Dec 23, 2022 |
| Dec 20, 2021 | $0.3972 | Dec 27, 2021 |
| Dec 21, 2020 | $0.6079 | Dec 28, 2020 |
| Dec 23, 2019 | $0.4724 | Dec 30, 2019 |
| Dec 20, 2018 | $0.551 | Dec 27, 2018 |
| Dec 18, 2017 | $0.683 | Dec 22, 2017 |
News
Brown Brothers Harriman Private Banking Team Expands in Philadelphia
PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...
Should You Invest in the VanEck Biotech ETF (BBH)?
Sector ETF report for BBH
VanEck Announces Yearend Distributions for VanEck Equity ETFs
NEW YORK--(BUSINESS WIRE)--VanEck announced today the following 2022 annual distributions per share for its VanEck® equity exchange-traded funds.
Biotech Finally Getting Its Groove Back
There's still plenty of room to run to return to prior highs, but some biotech stocks and exchange traded funds are showing signs of life. That's encouraging after what has been a surprisingly long do...
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
Biotech earnings have come in upbeat in the third quarter.
Assessing the Strength of Biotech Dividends With BBH
Biotechnology usually isn't the first industry investors think of when it comes to dividends, but some of the more mature companies in the space do deliver payouts. Some of those names reside in the V...
Consolidation Case for Biotech ETF BBH
Eight months into 2022, it's fair to say that it's been a tepid year of deal-making in the biotechnology industry, and that's one reason why the related stocks and exchange traded funds are scuffling.
Biotech Bounce-Back Could Be Durable
Following a lengthy wait that included plenty of downside and frustration, biotechnology stocks and exchange traded funds are finding a groove. For example, the VanEck Vectors Biotech ETF (BBH) is hig...
3 Best Funds for Aggressive Investors
The best funds for aggressive investors is our topic for today. An aggressive investing strategy typically seeks returns that are greater than those offered by the broader stock market, such as the S&...
Biotech Rebound Could Finally Be Afoot
A long-awaited biotechnology equity rebound could be materializing and some analysts believe it could have the momentum to carry into the end of 2022.
Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs
Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in i...
Bank on BBH for Surprising Protection
Owing to its reputation as a growth-heavy industry that's been disappointing investors since early 2021, biotechnology probably isn't the first destination investors think of when seeking shelter-from...
Biotech Stocks, ETFs Could Be Due for Second Half Rallies
Biotechnology stocks and the related exchange traded funds are in a prolonged slump, and along the way, calls for rebounds have been plentiful. They've also proven inaccurate.
Basic Could Be Beautiful When Biotech Bounces Back
Biotechnology stocks and exchange traded funds are into a second year of disappointing investors, but that condition won't be permanent. With that in mind, investors evaluating ideas for a biotech res...
Size Up SBIO as Biotech Catalysts Emerge
Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech ...
Betting on Biotech Bear Market Expiration Date
Since last year, biotechnology stocks and exchange traded funds have been among the most disappointing equity assets, wilting against the backdrop of the coronavirus pandemic and in advance of broader...
Positioning for Biotech Bounceback
Biotechnology stocks and exchange traded funds have frustrated investors for over a year now, but some analysts and experts believe that this gloomy trend will end soon. Investors willing to take that...
Biotech Stocks, ETFs Starting to Look Healthier
Amid a rebound in growth equities last week, biotech stocks and exchange traded funds got in on the act, and that could be a positive sign for a group that's long been slumbering. For example, the ALP...
Vaccine Stocks Lift Biotech ETFs as China Enters Lockdowns
Biotechnology sector-related exchange traded funds gained on Monday, with Moderna Inc. (NasdaqGS: MRN) sitting among the top performers in the S&P 500, on renewed COVID-19 concerns as China implements...
SBIO Is a Good Place to Be for Biotech Innovation
While biotechnology stocks and exchange traded funds continue frustrating market participants in the early innings of 2022, investors should not lose sight of the fact this corner of the healthcare se...
How Are Biotech ETFs Reacting to These Q4 Earnings Releases?
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Biotech ETFs Muddled Despite Amgen Strength
Biotechnology sector-specific exchange traded funds were flat after Amgen (NasdaqGS: AMGN) provided a mixed earnings report but announced that it will return value to investors through greater share b...
Omicron Vaccines to Hit Market Soon? ETF Areas to Benefit
Pfizer is likely to launch Omicron vaccine in March while Moderna is working on a booster that targets the omicron variant of Covid-19.